CORE in the News
Many patients receive a standardized lipid panel as part of a yearly physical that includes testing of their “good” cholesterol (high-density lipoprotein) and “bad” cholesterol (low-density lipoprotein). However, most people are unfamiliar with another type of cholesterol, lipoprotein(a) or Lp(a). This type of lipoprotein is not included in the standard lipid panel but is an independent risk factor for cardiovascular disease.
In the following Q&A, Yale clinicians and researchers share background about Lp(a), guidance for caring for patients with elevated levels, and new approaches to improve testing.
- June 26, 2024
Drugs for serious or life-threatening diseases can receive expedited U.S. Food and Drug Administration (FDA) review, allowing patients to receive faster access to promising new treatments. Under the expedited review pathway of accelerated approval, drugs can be FDA-approved based on surrogate markers or proxy measures such as changes in imaging or lab tests that are “reasonably likely” to predict whether patients improve in how they feel, function, or survive.
- June 19, 2024
YSPH Dean Megan L. Ranney, MD, and Ijeoma Opara, associate professor of social and behavioral sciences, are attending the Aspen Ideas: Health conference June 20-23 in Aspen, Colorado. Ranney will participate in three panel discussions; Opara is an Aspen Ideas: Health Fellow.
- June 14, 2024
The Yale PAX LC Trial’s decentralized, participant-centric design makes it more efficient and cost-effective than standard clinical trials, its investigators say.
- June 12, 2024Source: Yale New Haven Health
Yale New Haven Health (YNHHS) celebrated the second YNHHS Innovation Awards Ceremony, where five outstanding teams were each awarded $100,000 to bring their groundbreaking projects to life.
- June 11, 2024
Faculty from across the Yale Department of Internal Medicine are using artificial intelligence (AI) as a tool to help improve the way they learn, teach, conduct research, and advance the field of medicine.
- May 28, 2024
Surrogate markers of disease outcome aimed at speeding clinical trials are routinely accepted by the FDA for drug approvals, but most lack the requisite evidence.
- May 28, 2024
While more than 70% of people with hypertension cannot achieve adequate blood pressure control with just one drug, current guidelines only make recommendations for first-line therapy. Yuan Lu, ScD, assistant professor of medicine (cardiology) and assistant professor of biomedical informatics and data science and of epidemiology (chronic disease), recently received an R01 grant from the National Institutes of Health (NIH) to analyze real-world data to compare the effectiveness of second antihypertensive agents .
- May 23, 2024Source: Verywell.com
A new analysis of the longest study of the obesity medication Wegovy (semaglutide) shows it can help people safely lose weight and sustain it for at least four years.
- April 06, 2024
Yale investigators have identified a new artificial intelligence (AI)-based video biomarker that is able to identify those who might develop and have rapidly worsening aortic stenosis.